新型机器人平台与达芬奇多孔系统行机器人辅助根治性前列腺切除术的结局:系统综述与网络Meta分析
结果显示各平台围手术期指标存在差异,但肿瘤学与功能结局总体相当。
要点
- 达芬奇单孔系统淋巴结清扫与神经保留几率较低,但导管留置和住院时间更短
- Versius、康多和术锐单孔系统手术时间显著延长,Hugo RAS术中故障率更高
- 达芬奇单孔系统切缘阳性率较低,但会阴入路切缘阳性率更高
核心结论
- 各机器人平台行RARP的围手术期指标存在差异,但肿瘤学与功能结局总体相当。
研究设计与样本
- 采用随机效应模型进行网络Meta分析,连续变量以均数差表示,二分类变量以比值比(OR)及95%CI表示。
主要发现
- 与达芬奇多孔系统相比,达芬奇单孔系统淋巴结清扫几率较低(OR 0.39,95%CI 0.26-0.61),神经保留几率较低(OR 0.11,95%CI 0.02-0.61)。
- 达芬奇单孔系统导管留置时间缩短1.18天(95%CI -2.05至-0.31),住院时间缩短0.68天(95%CI -1.05至-0.31)。
- Versius、康多和术锐单孔系统手术时间显著延长(MD分别为74.00,95%CI 42.49-105.51;53.96,95%CI 18.26-89.67;103.88,95%CI 69.99-137.78)。
- Hugo RAS术中故障率较高(OR 6.53,95%CI 2.17-19.63)。
- 达芬奇单孔系统切缘阳性率较低(OR 0.70,95%CI 0.53-0.92),但会阴入路切缘阳性率较高(OR 6.30,95%CI 1.53-25.94);PSA持续、生化复发、控尿和勃起功能率各平台相当。
临床怎么用
- 平台选择需权衡围手术期差异(如单孔系统缩短住院但可能减少淋巴结清扫和神经保留)与肿瘤学安全性。
- 新型平台手术时间延长和故障率需纳入学习曲线与成本效益考量。
局限性
- 未来研究应关注学习曲线效应、成本效益和长期功能结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The introduction of novel robotic platforms has expanded surgical options for robot-assisted radical prostatectomy (RARP). However, comparative outcomes with da Vinci multiport (MP) system remain unclear. This systematic review and network meta-analysis aimed to compare perioperative, early oncological, and functional outcomes of RARP performed with novel robotic platforms versus the da Vinci MP system. METHODS: A systematic literature search was conducted in PubMed, Scopus, and Embase (updated December 22, 2024) following PRISMA guidelines. Eligible studies compared RARP performed with alternative robotic platforms versus da Vinci MP, reporting perioperative, oncological, or functional outcomes. A network meta-analysis was conducted using a random-effects model. Outcomes were expressed as mean differences for continuous variables and odds ratios (OR) for dichotomous variables, with 95% confidence intervals (CI). RESULTS: Thirty-three studies for a total of 5987 patients were included. Compared to da Vinci MP, da Vinci SP had lower odds of lymph node dissection (OR 0.39, 95% CI 0.26-0.61) and nerve-sparing (OR 0.11, 95% CI 0.02-0.61) but was associated with shorter catheterization (-1.18 days, 95% CI -2.05 to -0.31) and hospital stay (-0.68 days, 95% CI -1.05 to -0.31). Versius, KangDuo, and SHURUI SP had significantly longer operative times (MD 74.00, 95% CI 42.49-105.51; MD 53.96, 95% CI 18.26-89.67; MD 103.88, 95% CI 69.99-137.78, respectively). Hugo RAS had higher intraoperative malfunction rates (OR 6.53, 95% CI 2.17-19.63). Positive surgical margin rates were lower for da Vinci SP (OR 0.70, 95% CI 0.53-0.92) but higher with the perineal approach (OR 6.30, 95% CI 1.53-25.94). PSA persistence, biochemical recurrence, continence and erectile function rates were comparable across platforms. CONCLUSION: This is the first network meta-analysis comparing robotic platforms for RARP. While perioperative differences exist, oncological and functional outcomes appear comparable. Future studies should address learning curve effects, cost-effectiveness, and long-term functional outcomes to optimize robotic platform selection.
引用
- Chierigo F, Fallara G, Depalma M, et al. Outcomes of robot-assisted radical prostatectomy with novel robotic platforms vs da Vinci multiport systems: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis. 2025. PMID: 40921741. doi:10.1038/s41391-025-01023-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。